Eli Lilly and AbCellera Begin World's First Study of Potential COVID-19 Antibody Treatment in Humans
Eli Lilly and Company (Indianapolis, Ind, USA) has begun dosing patients in the world's first study of a potential antibody treatment designed to fight COVID-19.
Latest News
- COVID-19 Vaccine Likely to Be Ready by October This Year, Says Pfizer CEO
- Robotic Imaging Solution Detect Early COVID-19 Symptoms
- Novel Aspiration Catheter Treats Necrotizing Pancreatitis
- Ventilated COVID-19 Patients Could Benefit from Tracheotomy
- New Workstation Helps Meet COVID-19 Care Demands
- MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
- Novel Hydrocephalus Valve Addresses Postural Changes
- Blood Clotting Anomalies Reveal Renal Failure Risk in COVID-19
Product Showcase
LACTATE METER
The StatStrip Xpress handheld POCT system brings lactate testing directly to the patient’s bedside. It provides a tur... Read more...
